Loss of p16 does not protect against premature ovarian insufficiency caused by alkylating agents

BACKGROUND: Chemical agents such as alkylating agents (AAs) that are commonly used for the treatment of cancer cause great damage to the ovaries, thereby significantly increasing the risk of premature ovarian insufficiency (POI). However, the exact molecules underlying AA-induced POI remain largely...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Fei, Wan, Qin, Liu, Pengfei, Miao, Dengshun, Dai, Xiuliang, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993597/
https://www.ncbi.nlm.nih.gov/pubmed/36890528
http://dx.doi.org/10.1186/s12884-023-05476-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993597/
https://www.ncbi.nlm.nih.gov/pubmed/36890528
http://dx.doi.org/10.1186/s12884-023-05476-x

Ejemplares similares